Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
joby...I did not post this one yet because I have not done enough research on it to know if I feel it to be a good pick. That is why I asked the question I did. And, it would not fit in the $5 and under board as current price is over 10. I have posted several picks that I like here so far. When I post, it is on a stock I have researched and feel strongly about. Hope that answers your question.
Who here is good with DD for undervalued stocks that return $$$ in 2-6 months. If you only swing trade for $, I am not looking for that. I would like to share a few and exchange DD with someone who does similar investing as I have just described. Looking for my next AELA (in $2.95 Dec03 - 8.42 recently) and maybe I have another one.
Thanks
wrong board
AELA Another nice up day. More to come IMHO
AELA: Nice summary DD report link from analyst here
http://www.crystalra.com/pdf/AELA_NEW_EIO_05-13-04_Extranet.pdf
CEP.V more huge blocks almost 10X 3mo da avg
14:15 7.500 58,300 +0.000 Clarus Ntl. Bank Fin.
14:15 7.500 5,000 +0.000 Paradigm Ntl. Bank Fin.
14:15 7.500 5,000 +0.000 Paradigm Ntl. Bank Fin.
CEP.V HUGE Blocks. I posted DD on this. Ceramic Protection Corp. here is cut and paste of trades. Plus on huge block yesterday. This is Toronto Venture Exchange. Let m know if I am not supposed to post this exchange here. It is not an OTC stock.
13:33 7.600 500 +0.100 Ntl. Bank Fin. Ntl. Bank Fin.
13:14 7.500 42,600 +0.000 Clarus Clarus
13:10 7.500 50,000 +0.000 Clarus Clarus
12:41 7.600 1,200 +0.100 CIBC Ntl. Bank Fin.
11:06 7.500 150,200 +0.000 Clarus Clarus
SFLK - up 7% again.
MFLUTIE: A call with nice gain such as this is a good call no matter what system one uses. Nice!
Nice Earnings numbers DYTK. Moving up very well
AELA - Advancement of teverelix in phase IIa trials
Earlier today, Ardana Bioscience, the worldwide partner of AEterna/Zentaris for the development and marketing of teverelix, a LHRH antagonist, has separately announced the initiation of a phase IIa trial for patients with prostate cancer, as well as the planned initiation of a new phase IIa trial in patients with BPH to be started later this week. The advancement of teverelix into phase IIa follows a recently completed phase I trial which helped establish the dosage regimens necessary to achieve different levels of testosterone suppression.
Tag: good call IDNX is well worth a strong consideration IMHO
AELA, now 7.75 up 5.6% Alerted early enough. Much more to come IMHO!
AELA--AEterna/Zentaris to Present Detailed Positive Phase II Data on Cetrorelix and New Preclinical Data on Perifosine during Investor and Analyst Day in New York City
http://biz.yahoo.com/prnews/040517/mo193_1.html
AELA moving now back to HOD 7.71. up 3.55% for the day now 7.60 everything going at the ask, analyst conference time moved up to 1:15pm
Looks interesting on the first brief look for myself. Thanks! I will look some more at this one.
Thanks all for the emails. Glad you like the post AELA. If all goes well, you will like the move up.
AELA DD here, worth your read IMHO. Watch this climb next few days and continue next 3 weeks.
I will include a bunch of info in this post. I will bullet some of it in the beginning. Do your own checking but this is a quality stock to have during this next month beginning now.
- Analyst Conf tomorrow, went from 4.18 to $6.10 last time in Feb3/4, huge gain. Plus news came out after close AELA was added to NASDAQ Bioindex. Plus, this time they have "home Run" Phase II clinical results to tout. Plus, last conference the company mentioned possibility of spinning off Sub ATRIUM in an IPO.
- Company has 3 pieces of news due in the next 3 weeks.
- Current price of $7.34 is less than before the HUGE news ($7.60). After the news, the runup did not run anywhere near as much as it should have IMHO. It ran to only $8.42 (less than 11%!!!) Aeterna's chief executive, said "getting positive results from all indications, it's a 100 percent score, kind of a home run." Positive results in all 6 Phase II trials (and 11% run is all???) This is going to Phase III and should trigger a large payment from Solvay.
- Canadian $58M Rev 1st Q up 43%, Operating income was $1.6 million for the first quarter of 2004, compared with an operating loss of $1.3 million for the same period in 2003, primarily reflecting strong revenue growth of 62% from the majority-owned subsidiary Atrium. The net loss for the first quarter 2004 was $2.6 million, or $0.06 per share, a decrease of nearly 50% compared with a net loss of $4.9 million or $0.12 a share for the same period in 2003.
- DJ Loewen Ups Aeterna Tgt To C$16.25
- DJ Dundee Raises Aeterna Lab Tgt To C$14
- The ongoing clinical development of Perifosine in North America includes nine Phase II trials in six cancer types that are being conducted through collaboration between Zentaris GmbH, Keryx Biopharmaceuticals Inc. (Nasdaq: KERX - News) and the United States National Cancer Institute (NCI).
- Fact Sheet:
http://www.aeterna.com/aeterna/image/upload/Fact%20sheet%20-%20April%2029%202004 %20Eng.pdf
- company presentation:
http://www.aeterna.com/aeterna/image/upload/AELA%20PRESENTATION%20April%2029%202 004.pdf
And I am tired: Here is a bunch more I have collected. Some may be repeats.
=============
Aeterna Labs AELA
From a $4.18 close on Feb 3. to a $6.10 high the next day as a result of Analyst/Investor conference where product pipeline was discussed and where spinoff of subsidiary Atrium in an IPO was discussed as a possibility in 2004.
One of two lead compounds for Keryx, which is developing three clinical-stage oncology compounds including KRX-0401(Perifosine), a novel, oral, first-in-class AKT inhibitor in Phase II.
AEterna Laboratories Inc. along with its wholly-owned subsidiary Zentaris GmbH, announced today that results of the recently completed Phase I trial evaluating Perifosine, the Company's novel, first-in-class, oral AKT inhibitor in combination with radiotherapy in patients with unresectable locally advanced tumors will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in New Orleans, LA, June 5 through 8, 2004.
The ongoing clinical development of Perifosine in North America includes nine Phase II trials in six cancer types that are being conducted through collaboration between Zentaris GmbH, Keryx Biopharmaceuticals Inc. (Nasdaq: KERX - News) and the United States National Cancer Institute (NCI). AEterna, through Zentaris GmbH, holds ex-North America rights to Perifosine. To date, five Phase I trials have been conducted on Perifosine, including the trial to be highlighted at ASCO. In the four preceding trials, use of Perifosine as a single agent in a total of 94 patients provided initial, encouraging evidence of anti-tumor activity. Namely, investigators observed two partial responses (greater than 50% reduction) in patients with sarcoma and sixteen stable disease in patients with breast, prostate, pancreatic and other forms of cancer.
AEterna Laboratories Inc. along with its wholly-owned subsidiary Zentaris GmbH, is a biopharmaceutical company with an extensive product portfolio, including two marketed products and 14 other product candidates under development in oncology, endocrinology and infectious diseases. Cetrorelix (Cetrotide®) is sold in the U.S., Europe and several other countries to the in vitro fertilization market, and is in Phase II clinical trials for endometriosis, uterus myoma and enlarged prostate (BPH). Miltefosine (Impavido®) is sold for black fever and has successfully completed a Phase III trial in parasitic skin disease. Neovastat® is in a Phase III trial for non-small cell lung cancer. Perifosine, the first orally-active AKT inhibitor, is in Phase II trials for multiple cancers. Several other clinical programs are underway with various potential development candidates, supported by a worldwide network of scientific and marketing partnerships. Furthermore, AEterna benefits from a discovery platform of 100,000 molecules, which is generating promising new compounds.
AEterna also owns 62% of its subsidiary Atrium Biotechnologies Inc. which develops and markets active ingredients and speciality fine chemicals in the health and personal care industry for the cosmetics, chemical, pharmaceutical and nutritional industries. Its international business network and portfolio of over 1,000 products sold to over 2,000 institutional customers and to over 36,000 physicians and other health care professionals, have generated significant growth in sales and earnings since the Company was founded in January 2000. In 2003, Atrium sales exceeded $120 million.
Thursday April 29, 7:34 am ET AELA - News), along with its wholly-owned subsidiary Zentaris GmbH, today announced statistically significant positive results from a recently completed Phase II clinical program designed to evaluate cetrorelix, a luteinizing hormone releasing hormone (LHRH) antagonist, in three different indications: endometriosis, pre-surgical treatment of uterine myomas and benign prostatic hyperplasia (BPH), that can benefit from a targeted and controlled decrease in sex hormones, including estrogen and testosterone. The positive results of six Phase II trials, which also demonstrated good tolerability in all indications, will form the basis for further development of cetrorelix in different indications through collaboration with Solvay Pharmaceuticals, the Company's worldwide (ex-Japan) exclusive development and marketing partner for cetrorelix for the above indications.
"The striking results we have seen with cetrorelix in these trials, particularly in endometriosis, deliver on the promise of LHRH antagonists and are the culmination of many years of research and development efforts which originated from Dr. Schally's Nobel-Prize winning research into LHRH and its antagonists," said Prof. Jurgen Engel, Chairman & Managing Director of Zentaris GmbH, Executive Vice President R&D and Chief Operating Officer at AEterna. "Unlike other LHRH antagonists currently on the market or in clinical development, cetrorelix has a unique profile, avoiding total reduction (castration) of the different hormone levels. In addition, modulation of the epidermal growth factor receptor (EGFr) levels by cetrorelix has been shown in myoma cells, an effect that could be broadly applicable outside the cancer area."
"We are very excited about these positive Phase II results and are preparing a development plan in the different indications to expedite the registration of cetrorelix. We are especially enthusiastic about endometriosis for which no good treatment is currently available," stated Dr. Werner Cautreels, Solvay Pharmaceuticals' Global Head of R&D.
According to Gilles Gagnon, President and Chief Executive Officer at AEterna, "Cetrorelix, together with perifosine, form the cornerstone of our pipeline and, as such, we are very excited about the prospect of seeing cetrorelix enter pivotal trials in major markets. We look forward to further leveraging the depth and breadth of the product pipeline that we obtained through the acquisition of Zentaris to continue to deliver benefits to patients and value to our shareholders."
May 4 /PRNewswire-FirstCall/ - AEterna Laboratories Inc. (TSX: AEL - News; Nasdaq: AELA - News) today reported financial results for the first quarter ended March 31, 2004. Revenues for the first quarter 2004 were $58.4 million, an increase of 43% compared with $40.8 million for the same period in 2003. R&D expenses net of tax credits and grants decreased from $10.9 million in the first quarter of 2003 to $8.0 million in the first quarter of 2004, reflecting the realignment of the clinical development program initiated in December 2003, including the refocusing of the pipeline on perifosine and cetrorelix.
Operating income was $1.6 million for the first quarter of 2004, compared with an operating loss of $1.3 million for the same period in 2003, primarily reflecting strong revenue growth of 62% from the majority-owned subsidiary Atrium. The net loss for the first quarter 2004 was $2.6 million, or $0.06 per share, a decrease of nearly 50% compared with a net loss of $4.9 million or $0.12 a share for the same period in 2003.
=====
Who knows? I would prefer no buyout but....Here is an article worthy of a read.
http://news.ft.com/servlet/ContentServer?pagename=FT.com/StoryFT/FullStory&c=Sto ryFT&cid=1083180225004&p=1012571727108
Pfizer will acquire more biotechnology companies to fill out its pipeline of new medicines as it nears a point when several important drugs are expected to lose patent protection.
Hank McKinnell, chairman of the biggest pharmaceuticals group, said he preferred to purchase biotechnology companies, shifting from a strategy focused on licensing in marketing rights to promising experimental drugs.
"The one change you will see in this area is us doing a lot more acquisitions," he said.
His comments underline the tightening relationship between the two industries, with pharmaceuticals companies desperate for new products and many biotechnology groups short of cash.
Pfizer's strategy is aimed at preparing it for the 2006-07 period when it could lose protection on its patents for Norvasc, the hypertension drug, antidepressant Zoloft, antibiotic Zithromax and Zyrtec, an antihistamine.
Most biotechnology groups want licensing deals but Mr McKinnell believes the tough climate for small research-based companies will lead to agreements becoming acquisitions.
Pfizer indicated its intentions at the end of last year when it acquired Esperion, a US biotechnology company, for $1.3bn.
Mr McKinnell said many biotechnology companies had scaled back their ambitions, in part due to tougher conditions in capital markets but also because of the enormous risks involved in biomedical research.
"There was a time when 300 companies in the biotechnology space all wanted to grow up and be the next Pfizer, but I think they now recognise that this is pretty unlikely," he said. "Some of these companies have decided that, rather than follow their own strategy of growing the business or partnering with someone like us, they would rather be acquired at this point."
In the case of Esperion, he said, the two companies formed a partnership over its experimental cholesterol treatment based on high-density lipoprotein, or so-called good cholesterol, which could provide a boost to Pfizer's cardiovascular business.
Mr McKinnell said: "They realised that the probability of them partnering with us on this discovery and then going off and doing a whole new discovery was pretty remote."
Also, while a handful of biotechnology companies have become highly profitable, investors have become more sceptical about the prospects for s maller companies, which has made financing harder to find.
SFLK - alerted this morning. Up 12.6% and climbing now
SFLK - Transit worker IDs to be tested
By Bryon Okada
Star-Telegram Staff Writer
Posted on Fri, May. 14, 2004
WASHINGTON - The federal government is seeking management companies to test the Transportation Worker Identification Credential, a smart card that all transportation workers -- airport, seaport, rail, pipeline, trucking, mass transit -- must carry.
The cards will use biometric information, such as fingerprints, and will allow the federal government to send out targeted threat alerts to individual facilities.
Once the program is in place, a transportation worker cannot have unescorted access to secure areas without a card.
"This technology will not only improve security by keeping known terrorists away from vulnerable areas, but it also enhances the flow of commerce and protects individual privacy," David Stone, acting head of the Transportation Security Administration, said in a statement Wednesday.
The TSA will look only at companies that are approved vendors of smart-card technologies. They will be selected through the General Services Administration's Smart Access Common ID Card contract.
The prototype phase will be conducted with as many as 200,000 workers in Philadelphia; Wilmington, Del.; the ports of Los Angeles and Long Beach, Calif.; and the 14 major port facilities in Florida. Eventually, about 12 million workers are expected to be required to carry the card.
The TSA will roll out the cards nationwide after a seven-month test and a review.
Saflink SFLK Rodman & Renshaw Mkt Outperform. For what it is worth. Mid term here for me
SFLK, revs up Quarter Up 64% Sequentially and 34% Year-Over-Year , should move up today IMHO
To those who responded to my post:
Thanks for the replies and mail messages. I did not realize that many rarely ever post messages. Some of you just read and appreciate good posts. Again, thanks for the kind replies and for welcoming me here. I will post here from time to time when I have something I feel worthwhile to post.
How about this though: not just for me, but for anyone's DD that you read and you think was quality and informative, just drop them a reply mail or post and tell them thanks, very nice work. I will try to do more of that as well.
Magic, the DD on CEP: Not OTC, worse than that even, Venture Exchange Toronto. But such a sound company and I like finding these. If it were OTC or Nasdaq, it would be worth a whole lot more. Part of the reason it is attractive.
I also read about this boards rules regarding OTC stocks and will not post on those. I will say I got my first 10 bagger this week though with one of those. :D
Thanks for your replies and responses. I have always appreciated your input and learned a lot when you used to post on a certain other board.
I got a lot of feedback with my last post. It was all good. I did not realize there are so many who just lurk or read but do not post. I do now. And I realize I am being read when I post and even appreciated, but people just don't often post that.
Investing in stocks is not my full time job. It is what I do to augment what I earn from working for someone. I will never get rich working for someone else but may be able to do quite well as I build my knowledge about investing in stocks and build the worth of my portfolio when 'the ships come in'.
I will continue to post here from time to time. Thanks again.
Pehaps my last post here. Here is why.
There are several folks who post here that I have learned a good deal from, from other boards. I am appreciative and will continue to learn from them. But I joined this board to see what it was like and made a time consuming contribution of DD in Post #17953. Only reply I got was from Tag who welcomed me here. I even ask Magician, who I very much respect to read the DD and even by email. I have not gotten a response from anyone on the DD other than Tag. So, if no one is going to even read what I may post, why bother. I can just read other posts, take and never give. Since the giving is not read anyways.
Should this get read and any positive responses come, I may add some nice DD or other contributions from time to time here. If the DD I posted does not hold water, my gosh, say so so that I can learn. If it is good and you think the stock is promising, say so, whether you invest in it or not.
So, on that I will add one more stock contribution, AELA. Aeterna Labs. I am not going to post any of the DD I have done here at this time because it appears to be not read anyways. But I will say this stock is currently at $7.48. Between now and June 11, I think this will move to near $10 or better. Those that have read my posts elsewhere know I have been doing well on this one.
Lastly, this is not a slam towards anyone here. Not at all. It is just frustrating when you join and try to make a contribution and you get no response from anyone. I got other things I could do.
Thanks all and good luck.
magic see post #17953 Thanks
Thanks Tag, hope u enjoy the DD. I am trying to figure out all the things on investorhub. There is a lot here.
New poster - My initial contribution DD to this board - CEP.V Ceramic Protection Corp.
While one significant run up has occurred, I believe this company has so much more potential. It is sold on the TSX for Canadian start-up ventures. When/if it goes to NASDAQ or TSE or they announce plans to move, look out.
But that is not what is so enticing about the company. I will list a few of the items and you can do some of your own research.
Q1 results 64% increase in rev $6,542,000 CAD; 135% increase in Net income, EPS .012 vs. .05 CAD
Canadian Currency
Three Months Ended January 31 2004
(Thousands, except per share figures) 2004 2003
Sales $ 6,542 $ 3,988
Gross Profit 1,529 763
Net Income 809 344
EBITDA 1,161 474
Net Income per Share 0.12 0.05
EBITDA per Share 0.17 0.07
-- Earnings were impacted negatively in December as a
result of an unacceptable variability in certain raw materials used in manufacturing. These difficulties, which reduced ceramic armour plate production, were resolved with suppliers and normal production was resumed in early January.
Wow! Negatively impacted? And, this states that normal production resumed early January. I would think some of that production return would carry over to this quarter as well.
Outlook
The Corporation experienced strong demand for its products in the first quarter. It is expected that sales for personnel armour will continue to be strong in the near term and the Corporation continues its work on vehicular armour applications for the longer term. New wear management products, notably ceramic lined choke valves used in SAGD applications, offer longer term sales opportunities.
Vehicular armor - this has to do with work the comapny is doing with an auto manufacturer to provide ceramic door protection for police vehicles as standard equipment."The Corporation continued its development, with the support of the National Research Council of Canada IRAP program, of ballistic panels to be used in police vehicles. This advanced ballistic system, with the significant competitive advantage of being designed for installation by the original vehicle manufacturer on the assembly line, has received encouraging interest from police agencies across North America. At the time of writing, the Corporation is pursuing engineering and technical evaluations with the manufacturer to merge and adapt existing automotive manufacturing processes and procedures to allow for efficient assembly line installation of the ballistic panels.
From Annual Report - "In the past year, the Corporation has continued its work with an automotive manufacturer in Detroit, Michigan, for the development of ballistic door panels for police vehicles. Should these efforts be successful, significant future sales are anticipated."
The risk is 'should these efforts be successful'. The reward, could be substantial.
Oil extraction - Ceramic choke valves in SAGD applications:
They identified the application, went to a major oil company to develop it, and the first sale was $500,000 for 28 valves, $17,000 per valve. SAGD (steam assisted gravity drainage) is what unlocks the second biggest oil reserve in the world, tar sands in Canada have never been counted as recoverable resources until SAGD made recovey possible, cost is $6/ barrel so at current world price, VERY PROFITABLE. SAGD projects that are starting up are huge, and have 100 to 400 paired wells per project, BUT just as important they have developed a range of new applications for the oil and gas industry...
"the development of a new ceramic-lined choke valve for heavy oil (SAGD) production has allowed the Corporation to work with major oil producers in Canada to evaluate and apply these advanced solutions. Some of our technologies are at, or near, the commercial deployment stage"
Outlook
The Corporation has experienced strong demand for its products during the past year. The international marketplace continues to require the products offered by the Corporation and it is expected that, at a minimum, demand and sales will remain strong for the near term. The Corporation is also anticipating growth in the longer term through sales in the vehicular armour segment of the marketplace.
Other notes:
-15M backlog
-In Feb, the company announced new orders worth CAD $2,600,000, for ceramic armour and industrial products manufactured by the Corporation. These orders add to a strong order book already in place for the remainder of 2004
-In March, the company announced that it has recently received new orders from a customer in the United States amounting to CAD $8.6 million. The customer is a major integrated body armour manufacturer that supplies personnel body armour systems to the U.S. military. The new orders are for polyethylene plate products distributed by the Corporation and for ceramic personnel plates manufactured by the Corporation.
Dr. Ron Wallace, Chief Executive Officer, stated: "These new orders are indicative of the Corporation's continued and successful efforts to win significant orders in the competitive international body armour marketplace. The international armour systems market remains very strong. The Corporation's integrated capability to manufacture ballistic ceramics used in our completed bonded plates as well as distribute other ballistic products for personnel armour systems has contributed to our competitive advantage in winning these orders."
-In April announced it has recently received three new orders from two major integrated armour manufacturers in the United States. The customers manufacture armour systems for the U.S. military. One of the orders is for a ballistic fiber product now distributed by the Corporation. The remaining two orders are for two types of ballistic ceramic plates. The three orders have a total value of approximately CAD $2.5 million
-New product, same April release: New Ballistic Fiber Product
The sale of the ballistic fiber follows from a distribution agreement recently concluded by the Corporation with a holder of a patent for advanced aramid fibers. The total amount of this order is approximately CAD $800,000. This sale is the first for the Corporation as distributor of this fiber. This advanced fiber is also used by the Corporation to manufacture completed personnel armour plates. The Corporation is conducting preliminary evaluations as to the feasibility of manufacturing the material in house. Dr. Ron Wallace, Chief Executive Officer, stated: "This initiative represents an added capability of the Corporation to provide a full range of ballistic materials for the integrated ballistic systems marketplace. This new product represents another exciting direction for the Corporation to manufacture, market and distribute a wider range of products to customers."
- What will May bring? Guess that remains to be seen.
OK, I have done this much leg work and posting. You can apply the charts and other technicals.
Let me know what you think and if you appreciated this post and am I welcome here?
Thanks and best of luck.
Thought I would check out this place. Hello to magic, tag and mflutie